<?xml version="1.0" encoding="UTF-8"?>

<rootTag>
  <Award>
    <AwardTitle>SBIR Phase II: Scale-up Manufacturing of Nitric Oxide Nanotechnology for Healthcare Infections</AwardTitle>
    <AwardEffectiveDate>11/01/2011</AwardEffectiveDate>
    <AwardExpirationDate>12/31/2013</AwardExpirationDate>
    <AwardAmount>990032</AwardAmount>
    <AwardInstrument>
      <Value>Standard Grant</Value>
    </AwardInstrument>
    <Organization>
      <Code>07070000</Code>
      <Directorate>
        <LongName>Directorate For Engineering</LongName>
      </Directorate>
      <Division>
        <LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
      </Division>
    </Organization>
    <ProgramOfficer>
      <SignBlockName>Rajesh Mehta</SignBlockName>
    </ProgramOfficer>
    <AbstractNarration>This Small Business Innovation Research (SBIR) Phase II project aims to develop the process and engineering controls necessary to scale up the manufacturing of a nitric-oxide-releasing active pharmaceutical ingredient (API). One of the applications is a wound-healing product for diabetic foot ulcers. This project will focus on 1) optimizing the process parameters required to scale production of a nitric-oxide-releasing API to reproducible 1 kg batches, and 2) implementing the analytical methodologies to meet the requirements of the Chemistry, Manufacturing and Control (CMC) sections of an Investigational New Drug (IND) application. The expected outcome is a manufacturing process capable of producing large batches of the API that are suitable for an IND submission of a wound-healing product for diabetic foot ulcers or other nitric-oxide-releasing drug. &lt;br/&gt;&lt;br/&gt;The broader/commercial impacts of this project will be the potential to provide a new standard of care for the treatment of diabetic foot ulcers. Currently, there are no products that address both wound healing and infection in diabetic foot ulcers. Infection is particularly problematic in diabetic foot ulcers due to the lack of normal skin barrier function, long duration of wound exposure to the external environment (months to years), poor blood circulation to the extremities that limits the migration of inflammatory cells to the site of infection, and the recent understanding of biofilm formation which protects bacteria from topically applied antimicrobials and systemically administered antibiotics. Nitric-oxide-releasing wound-healing therapeutics have the potential of addressing both infection and healing in diabetic foot ulcers.</AbstractNarration>
    <MinAmdLetterDate>10/24/2011</MinAmdLetterDate>
    <MaxAmdLetterDate>12/18/2013</MaxAmdLetterDate>
    <ARRAAmount/>
    <AwardID>1127380</AwardID>
    <Investigator>
      <FirstName>Nathan</FirstName>
      <LastName>Stasko</LastName>
      <EmailAddress>nstasko@novanonline.com</EmailAddress>
      <StartDate>10/24/2011</StartDate>
      <EndDate/>
      <RoleCode>Principal Investigator</RoleCode>
    </Investigator>
    <Institution>
      <Name>Novan, Inc.</Name>
      <CityName>Durham</CityName>
      <ZipCode>277038030</ZipCode>
      <PhoneNumber>9194858080</PhoneNumber>
      <StreetAddress>4222 Emperor Blvd</StreetAddress>
      <CountryName>United States</CountryName>
      <StateName>North Carolina</StateName>
      <StateCode>NC</StateCode>
    </Institution>
    <ProgramElement>
      <Code>5373</Code>
      <Text>SMALL BUSINESS PHASE II</Text>
    </ProgramElement>
    <ProgramReference>
      <Code>084E</Code>
      <Text>NANOMANUFACTURING</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>1084</Code>
      <Text>NANOTECHNOLOGY INITIATIVE</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>165E</Code>
      <Text>SBIR Phase IIB</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>1788</Code>
      <Text>Nanomanufacturing</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>5373</Code>
      <Text>SMALL BUSINESS PHASE II</Text>
    </ProgramReference>
  </Award>
</rootTag>
